Wanbury Limited appoints Mr. Pradeep Patni as CEO of India Formulation Business

Wanbury Limited has announced the appointment of Mr. Pradeep Patni as the Chief Executive Officer (CEO) of its India Formulation Business. Mr. Patni brings over 25 years of distinguished experience in the pharmaceutical industry, having most recently served as CEO at Akumentis. During his 4 - year tenure (FY21-24) at Akumentis, Mr. Patni, along with the leadership team, drove remarkable growth in sales, which increased by 1.7 times from Rs. 233 crore in FY21 to Rs. 398 crore in FY24. Additionally, the EBITDA margin improved significantly, rising from 4% in FY21 to 21 % in FY24.

An MBA from IIM Bangalore, Mr. Patni has a rich background in managing independent business units within leading multinational pharmaceutical corporations. His broad expertise spans both patented and generic molecules, as well as bio-therapeutics, enabling him to navigate diverse markets and portfolios effectively. Throughout his career, Mr. Patni has consistently delivered on organizational objectives.

Mr. Patni, began his career at Ranbaxy Labs and has since built a successful professional trajectory in the pharmaceutical industry, having worked with companies such as Janssen (10 years), Pfizer Ltd. (6 years), Abbott Healthcare (6 years) and Micro Labs.

Wanbury Limited is confident that under Mr. Patni's leadership, the India Formulation Business will achieve new heights of success, driving growth and reinforcing its commitment to excellence.

Shares of Wanbury Limited was last trading in BSE at Rs. 201.25 as compared to the previous close of Rs. 195.90. The total number of shares traded during the day was 40408 in over 1268 trades.

The stock hit an intraday high of Rs. 205.65 and intraday low of 192.85. The net turnover during the day was Rs. 8134291.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Appointment CEO IndiaFormulationsBusiness